53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes ... portfolio and increases access to biologics for patients suffering from chronic inflammatory diseases, such as ...

The findings demonstrate that AD disease activity remained mild in patients who had achieved ... Biologics License Application (BLA) for HLX14, biosimilar candidate of PROLIA/XGEVA (denosumab).

Overall, the study’s findings support the use of Amjevita and Imraldi as equally effective alternatives to Humira in the real ...

HYDERABAD, India and REYKJAVIK, Iceland, March 18, 2025 (GLOBE NEWSWIRE) -- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY ...

Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE ...

The inquiry is the latest effort by the European Commission and European countries to scrutinize potential antitrust behavior ...

Dr. Reddy’s Laboratories RDY and partner, Alvotech ALVO, announced the FDA’s acceptance of a regulatory filing, seeking the ...

Sanofi-Aventis' Merilog version of the product has been cleared for the treatment of adult and paediatric patients with type 2 diabetes. It is the first biosimilar of a rapid-acting insulin ...

In fact, the success of biosimilars in Europe has given the United States a glimpse into how these therapies can increase patient access to the benefits of the most innovative therapies.

Tendering emerged as the most effective strategy for reducing costs and increasing biosimilar uptake in the retail setting, ...